RBC Capital lowered the firm’s price target on BioMarin (BMRN) to $66 from $70 and keeps a Sector Perform rating on the shares. The company reported an in-line quarter given the Voxzogo miss was offset by the base business beat, the analyst tells investors in a research note. On Voxzogo, this is the very first down quarter since launch, and BioMarin notes some seasonality and a somewhat mixed uptake in older US kids, RBC added.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on BMRN:
- BioMarin Pharmaceutical: Undervalued Growth Potential and Strategic Positioning Support Buy Rating
- BioMarin price target lowered to $73 from $91 at Stifel
- BioMarin Pharmaceutical: Strong Growth Prospects and Strategic Initiatives Justify Buy Rating
- BioMarin price target lowered to $98 from $104 at Morgan Stanley
- BioMarin price target lowered to $102 from $103 at BofA